

SEP 16 2005  
Please type a plus sign (+) inside this box 

+

09-19-05

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JFW 1647

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/017,081
		Filing Date	October 24, 2001
		First Named Inventor	Avi J. Ashkenazi
		Group/Art Unit	1647
		Examiner Name	Robert S. Landsman
Total Number of Pages in This Submission	110	Attorney Docket Number	39780-2630 P1C69

## ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Response/Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Version With Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Information Disclosure Statement with 14 References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 <input type="checkbox"/> Copy of Notice	<input type="checkbox"/> Copy of an Assignment <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW): <input checked="" type="checkbox"/> Return Postcard
Remarks		

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-2630P1C69.

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN LLP 275 Middlefield Road, Menlo Park, California 94025	BARRIE D. GREENE (Reg. No. 46,740) Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature		
Date	SEPTEMBER 16, 2005	Customer Number: 35489

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: SEPTEMBER 16, 2005

Express Mail Label EL 976 548 777 US

Typed or printed name	L. ACOSTA		
Signature		Date	SEPTEMBER 16, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop       , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

09/21/2005 10:00:00 000000031 046731 10017481  
01 01 10:00:00



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2005

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** **(\$)** **180.00**
**Complete if Known**

Application Number	10/017,081
Filing Date	October 24, 2001
First Named Inventor	Avi J. Ashkenazi
Examiner Name	Robert S. Landsman
Art Unit	1647
Attorney Docket No.	39780-2630 P1C69

**METHOD OF PAYMENT (check all that apply)**
 Check  Credit card  Money Order  Other  None
 Deposit Account:

Deposit Account Number	08-1641 (39780-2630P1C69)
Deposit Account Name	HELLER EHRMAN, LLP

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

**FEE CALCULATION (continued)****3. ADDITIONAL FEES****Large Entity** **Small Entity**

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)** **180.00**

\*\*or number previously paid, if greater; For Reissues, see above

(Complete if applicable)

**SUBMITTED BY**

Name (Print/Type)	Barrie D. Greene	Registration No. (Attorney/Agent)	46,740	Telephone	(650) 324-7000
Signature	<i>Barrie D. Greene</i>	Date	September 16, 2005		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



09-19-05

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ) Examiner: Landsman, Robert S.  
Avi J. ASHKENAZI, et al. )  
Application Serial No. 10/017,081 ) Art Unit: 1647  
Filed: October 24, 2001 ) Confirmation No: 4135  
For: **SECRETED AND TRANSMEMBRANE** ) Attorney's Docket No. 39780-2630P1C69  
**POLYPEPTIDES AND NUCLEIC** )  
**ACIDS ENCODING THE SAME** ) Customer No. 35489

---

EXPRESS MAIL LABEL NO. EL 976 548 777 US  
DATE MAILED: SEPTEMBER 16, 2005

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

#### MAIL STOP AMENDMENT

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form Supplemental PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

09/21/2005 JBALINAN 00000031 10017081

01 FC:1806 180.00 DA

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --

(2) It is being filed within 3 months of entry of a national stage  
-- OR --

(3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.97(e) is provided below; **or**

a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; **and**


B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

*Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2630 P1C69)**.

Respectfully submitted,

Dated: September 16, 2005

  
Barrie D. Greene (Reg. No.46,740)

**HELLER EHRLMAN, LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SEP 16 2005

Form PTO-1449

Attorney's Docket No.  
39780-2630 P1C69Application Serial No.  
10/017,081

## INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Avi J. ASHKENAZI et al.

(use several sheets if necessary)

Filing Date:  
October 24, 2001Group Art Unit:  
1647

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation
							YES
							NO

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	1.	Dayhoff, Accession No.: P_AAB65300, WO 200073454-A1, Pub Date: December 7, 2000, A. J. Ashkenazi et al.
	2.	Dayhoff, Accession No.: P_AAB19580, WO 200053760-A2, Pub Date: September 14, 2000, N. Ferrara et al.
	3.	Dayhoff, Accession No.: P_AAB44273, WO 200053756-A2, Pub Date: September 14, 2000, A. J. Ashkenazi et al.
	4.	Dayhoff, Accession No.: P_AAY41717, WO 9946281-A2, Pub Date: September 16, 1999, W. I. Wood et al.
	5.	Dayhoff, Accession No.: P_AAB27653, WO 200053757-A2, September 14, 2000, A. J. Ashkenazi et al.
	6.	GenBank, Accession No.: P_AAF44269, WO 200073454-A1, Pub Date: December 7, 2000, A. J. Ashkenazi et al.
	7.	GenBank, Accession No.: P_AAA88517, WO 200053760-A2, Pub Date: September 14, 2000, N. Ferrara et al.
	8.	Benjamin et al., "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal", Proc, Natl. Sci USA, Vol. 94, pp 8761-8766, August 1997.
	9.	Bozyczko-Coyne et al., "A rapid fluorometric assay to measure neuronal survival in vitro", Journal of Neuroscience Methods, Vol. 50, pp 205-216, 1993.
	10.	Fontaine et al., "Survival of Purified Rat Photoreceptors In Vitro Is Stimulated Directly by Fibroblast Growth Factor-2", The Journal of Neuroscience, Vol. 18, No. 23, pp 9662-9672, December 1, 1998.
	11.	Jiang et al., "Selenium-Induced Inhibition of Angiogenesis in Mammary Cancer at Chemopreventive Levels of Intake", Molecular Carcinogenesis, Vol. 26, pp 213-225, 1999.
	12.	Levin et al., "Effect of Lipid Peroxidation Inhibition on Retinal Ganglion Cell Death", Investigative Ophthalmology & Visual Science, Vol. 37, No. 13, December 1996.
	13.	Otori et al., "Neurotoxic Effects of Low Doses of Glutamate on Purified Rat Retinal Ganglion Cells", Investigative Ophthalmology & Visual Science, Vol. 39, No. 6, May 1998.
	14.	Otori et al., "Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells", Brain Research, Vol. 961, pp 213-219, 2003.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2153473 v1	